For patients recently diagnosed with prostate cancer, the emerging positron emission tomography (PET) agent 18F-rhPSMA-7.3 reportedly has a 96 percent specificity rate for detecting pelvic lymph node metastases, according to Phase 3 study results recently presented at the 22nd Annual Scientific Meeting of the Society of Urologic Oncology (SUO).
While conventional imaging and procedures have limitations in the assessment of pelvic lymph node metastases in people with prostate cancer, new research suggests that an investigational positron emission tomography (PET) agent may be beneficial in this patient population.
In a Phase 3 trial of 296 patients recently diagnosed with prostate cancer, researchers assessed use of the prostate-specific membrane antigen (PSMA) agent 18F-rhPSMA-7.3 (Blue Earth Diagnostics/Bracco Imaging) with PET imaging prior to the patients undergoing radical prostatectomy and pelvic lymph node dissection (PLND).
According to a recent presentation of study results at the 22nd Annual Scientific Meeting of the Society of Urologic Oncology (SUO), researchers found that 18F-rhPSMA-7.3 had a 96 percent specificity rate (217 of 226 patients) for detecting pelvic lymph node metastases. The study authors also noted that 18F-rhPSMA-7.3 had a sensitivity rate of 24 percent, a finding that is “consistent” with sensitivity rates reported with other PSMA-targeted radiopharmaceuticals.
Brian F. Chapin, M.D., a co-author of the study, suggested that PET imaging with 18F-rhPSMA-7.3 may provide additional clarity with the staging of people with primary prostate cancer.
“Up to 25 percent of patients with primary prostate cancer may have detectable pelvic lymph node metastases, which are correlated with a risk for recurrence and associated overall survival,” noted Dr. Chapin, an Associate Professor in the Department of Urology in the Division of Surgery at the University of Texas MD Anderson Cancer Center. “Conventional imaging techniques, such as (magnetic resonance imaging and computed tomography), are limited in the information they may provide. Pelvic lymph node dissection (PLND), or pelvic lymphadenectomy, is considered the gold standard in assessing pelvic node lesions, but its use is limited to the planned surgical area. An ideal staging technique for detecting metastatic prostate cancer should include both pelvic nodes as well as more distant soft tissue and skeletal findings.”
The researchers also noted no serious adverse effects with the use of 18F-rhPSMA-7.3. While the study authors noted a 7.9 percent incidence of adverse events that may have been attributed to use of the imaging agent, they noted that injection site pain was the most reported adverse event in 0.8 percent of the study participants.
(For related content, see “Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?” and “Can MRI-Based Prostate Cancer Screening be a Viable Alternative to PSA Testing?”)
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer
July 8th 2024For men with prostate cancer, new research demonstrates that 18F-PSMA-1007 PET/CT is 17 percent more accurate than mpMRI at identifying the final pathological tumor stage and 12 percent more accurate in detecting extracapsular extension.
Could MRI-Based AI Offer Better Risk Stratification for Prostate Cancer than PI-RADS?
July 3rd 2024The combination of deep learning assessment of prostate MRI with PI-RADS classification at a 15 percent risk threshold spared 49 percent of biopsies in comparison to 37 percent employing a PI-RADS>4 only cut-ff approach, according to new research.